Business Context and Reporting Period
This Form 8-K was filed by Karyopharm Therapeutics Inc. on February 15, 2023, reporting events occurring on February 9 and February 10, 2023. The filing details the approval of annual equity awards under the Company's 2022 Equity Incentive Plan for key executive officers.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes
The primary material change reported is the grant of equity awards to two senior executives, effective February 28, 2023:
- Michael Mason (EVP, CFO, Treasurer): Granted 95,000 time-based Restricted Stock Units (RSUs) and 80,000 target Performance-Based RSUs (PSUs).
- Richard Paulson (President, CEO): Granted 252,000 time-based RSUs and 252,000 target PSUs.
Guidance, Outlook, and Management Commentary
The filing outlines the performance criteria for the PSUs, which vest based on three equally weighted objectives (33% each) over a period ending December 31, 2025:
- Revenue Objective: Based on total net revenue from January 1, 2023, to December 31, 2025. Vesting ranges from 16 2/3% (threshold) to 66 2/3% (maximum) of the target amount.
- Milestone Objective: Based on the achievement of three clinical milestones. Vesting ranges from 16 2/3% (one milestone) to 66 2/3% (three milestones). No clinical milestone PSUs may vest prior to the first anniversary of the grant date.
- Relative TSR Objective: Based on the Company's Total Shareholder Return relative to the NASDAQ Biotechnology Index. Vesting ranges from 16 2/3% to 66 2/3% based on percentile ranking.
The total number of PSUs that may vest ranges from 0 to a maximum of 200% of the target number granted.
Investor Verification Checklist
- Verify the specific clinical milestones defined in the attached Restricted Stock Unit Agreement (Exhibit 10.1).
- Confirm the exact revenue thresholds required to trigger the 16 2/3%, 33 1/3%, and 66 2/3% vesting levels.
- Review the Company's 2022 Equity Incentive Plan to understand the total pool of shares available for future grants.
- Monitor the Company's quarterly financial reports to track progress against the three-year revenue objective.